Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Issues Draft Guidance Concerning the Type and Quality of Scientific Evidence Underlying Structure/Function Claims Made in Infant Formula Labels and LabelingCFSAN Constituent Updates FDA Issues Draft Guidance Concerning the Type and Quality of Scientific Evidence Underlying Structure/Function Claims Made in Infant Formula Labels and Labeling
  
  	
    Share
    Post
    Linkedin

    Email
    PrintWhat's New

November 18, 2016

The FDA is reopening the comment period on the draft guidance for industry about the type and quality of scientific evidence substantiating structure/function claims made in infant formula labels and labeling.

The FDA is taking this action in response to requests for additional time to submit comments. The comment period will reopen on November 21, 2016 and close on February 21, 2017.

For additional information, see the Federal Register Notice for the reopening of the comment period.

Original Constituent Update

September 9, 2016

The U.S. Food and Drug Administration has issued draft guidance for industry to help infant formula manufacturers making structure/function claims comply with the requirement that all claims in infant formula labels and labeling be truthful and not misleading.

“Structure/function” claims are statements made about the effects of a product or its constituent on the normal structure or function of the body. An example of a structure/function claim in infant formula labeling is a statement that the formula “supports digestion.”

In the draft guidance, “Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,” the FDA describes its recommendations for the type and quality of scientific evidence that is appropriate to substantiate (i.e., support) structure/function claims made about an infant formula by the product’s manufacturers or distributors. The draft guidance provides recommendations with respect to all infant formulas, including formulas marketed for use by infants who have inborn errors of metabolism or low birth weight, or who otherwise have unusual medical or dietary problems.

The FDA does not preapprove structure/function claims in the labeling of foods (including infant formula).This draft guidance specifically focuses on infant formula, which provides the sole or a primary source of nutrition for many infants during a critical period of growth and development. This vulnerable population is entirely dependent upon caregivers who must be able to trust that the information on the label is truthful and scientifically supported.

The comment period on this draft guidance opens September 9, 2016. Although comments are accepted at any time, to ensure that the agency considers comments on this draft guidance before it begins work on the final version of this guidance, submit either electronic or written comments on the draft guidance by November 8, 2016. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number FDA-2016-D-2241, as listed in the notice of availability that publishes in the *Federal Register*.

**For More Information**

Draft Guidance for Industry: Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling
	Federal Register Notice

                                                                                  Content current as of:
      12/11/2017
              
              
Regulated Product(s)
		 Food & BeveragesCFSAN Constituent Updates
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop